Blueprint Medicines Corp (BPMC) Expected to Announce Earnings of -$1.55 Per Share
Wall Street brokerages forecast that Blueprint Medicines Corp (NASDAQ:BPMC) will post earnings per share of ($1.55) for the current quarter, according to Zacks. Three analysts have made estimates for Blueprint Medicines’ earnings. The highest EPS estimate is ($1.33) and the lowest is ($1.73). Blueprint Medicines posted earnings per share of ($0.96) in the same quarter last year, which suggests a negative year-over-year growth rate of 61.5%. The company is scheduled to announce its next quarterly earnings results on Tuesday, October 30th.
On average, analysts expect that Blueprint Medicines will report full-year earnings of ($5.13) per share for the current fiscal year, with EPS estimates ranging from ($5.61) to ($4.58). For the next financial year, analysts expect that the firm will report earnings of ($7.18) per share, with EPS estimates ranging from ($9.78) to ($5.51). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.70. Blueprint Medicines had a negative net margin of 326.99% and a negative return on equity of 32.61%. The business had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $2.62 million. During the same period last year, the business earned ($0.86) earnings per share. The firm’s revenue was up 602.9% on a year-over-year basis.
In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 20,000 shares of the firm’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $70.59, for a total transaction of $1,411,800.00. Following the completion of the sale, the chief executive officer now owns 20,000 shares of the company’s stock, valued at approximately $1,411,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.15% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Swiss National Bank lifted its holdings in Blueprint Medicines by 3.9% during the 1st quarter. Swiss National Bank now owns 67,200 shares of the biotechnology company’s stock valued at $6,162,000 after purchasing an additional 2,500 shares during the last quarter. Lisanti Capital Growth LLC lifted its holdings in shares of Blueprint Medicines by 29.4% during the first quarter. Lisanti Capital Growth LLC now owns 24,860 shares of the biotechnology company’s stock worth $2,280,000 after buying an additional 5,650 shares in the last quarter. Alkeon Capital Management LLC lifted its holdings in shares of Blueprint Medicines by 1,015.8% during the first quarter. Alkeon Capital Management LLC now owns 111,575 shares of the biotechnology company’s stock worth $10,231,000 after buying an additional 101,575 shares in the last quarter. Zeke Capital Advisors LLC acquired a new stake in shares of Blueprint Medicines during the first quarter worth $207,000. Finally, Guggenheim Capital LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $2,739,000. 97.60% of the stock is owned by institutional investors and hedge funds.
Blueprint Medicines opened at $68.86 on Thursday, MarketBeat Ratings reports. Blueprint Medicines has a 1-year low of $41.41 and a 1-year high of $109.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.36 and a current ratio of 12.36.
About Blueprint Medicines
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Story: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.